Investors: Look beyond Merck's patent loss

  @Money May 1, 2013: 6:17 AM ET
merck singulair

Merck's diabetes drug, Januvia, is expected to add $750 million to sales growth annually through 2020.

(Money Magazine)

Big Pharma is back, with shares of giant drug manufacturers doubling the returns of the broad market over the past six months. Yet Merck has been conspicuously left behind.

Since last fall -- shortly after the patent on top seller Singulair expired, exposing the asthma drug to cheap competition -- Merck (MRK, Fortune 500) shares have sunk 3%. Adding to the Street's fears: the company's difficulties in developing next-generation blockbusters. What investors don't realize, though, is that Merck's patent and pipeline problems aren't as dire as they seem.

Less vulnerable
Product development is a problem -- but it's hardly the whole story.
Potential drug revenue loss to generics: 2014-2017
Merck 2.8%
Pfizer 4.7%
Eli Lilly 11.6%
Source: Morningstar

Loss of Singulair patent

For nearly a decade, drug manufacturers have been plagued by patent expirations, which have allowed makers of cheaper generic drugs to swoop in and take revenues.

"The large pharmaceutical companies have all been going through this," says Erich Patten of the Cutler Equity Fund, which owns Merck shares. Pfizer (PFE, Fortune 500) experienced it in 2006 with the antidepressant drug Zoloft and in 2011 with its cholesterol fighter Lipitor. "It's just been Merck's turn recently," Patten says.

After Singulair went off patent, quarterly sales of the respiratory medication plunged from $1.5 billion in the fourth quarter of 2011 to $480 million late last year. Investors are now waiting to see if Merck can recover the way that Pfizer did.

A healthy pipeline

The loss of Singulair is a big blow, but, going forward, patent expirations threaten less than 3% of Merck's sales -- far less than the industry average.

Merck also "has one of the healthiest base business of its U.S. major-pharma peers, putting less pressure on the company's pipeline to generate growth," noted J.P. Morgan analyst Chris Schott in a recent report.

How Novartis develops blockbuster drugs

The diabetes drug Januvia, for instance, is becoming as big as Singulair was and is expected to add $750 million to sales growth each year from now through 2020.

Related: Reduce the steep cost of diabetes

As for new blockbusters, clinical trials of treatments for osteoporosis, cholesterol, and heart disease have been disappointing. To turn things around, though, Merck has hired the former chief of R&D at Amgen.

A generic price

Even with the Singulair loss, Merck's overall revenue is expected to grow 2% annually for the rest of the decade. Though modest, that's in line with the industry average and slightly ahead of sales growth at its chief rivals. As for Merck's earnings, they're expected to climb at a healthier 8% annual clip.

Related: 6 high-dividend, blue-chip stocks

Despite these facts, investors continue to fixate on Singulair. Merck shares are trading at cheap levels relative to the industry average and pay a generous 4.0% yield. That payout is driven in part by Merck's industry-leading cash cushion of more than $13 billion, a stash that has also helped the drug giant spend more on R&D last year than rivals Eli Lilly, (LLY, Fortune 500) Pfizer, and Bristol-Myers Squibb (BMY, Fortune 500). To top of page

Join the Conversation
Sponsored by
Index Last Change % Change
Dow 16,424.85 162.29 1.00%
Nasdaq 4,086.23 52.07 1.29%
S&P 500 1,862.31 19.33 1.05%
Treasuries 2.64 0.01 0.34%
Data as of 11:13pm ET
Company Price Change % Change
Bank of America Corp... 16.13 -0.26 -1.59%
Facebook Inc 59.72 0.63 1.07%
Yahoo! Inc 36.33 2.12 6.20%
Intel Corp 26.93 0.16 0.60%
Alcoa Inc 13.42 0.37 2.84%
Data as of 4:02pm ET
Overnight Avg Rate Latest Change Last Week
30 yr fixed4.41%4.44%
15 yr fixed3.33%3.31%
5/1 ARM3.34%3.55%
30 yr refi4.39%4.41%
15 yr refi3.31%3.30%
View rates in your area
Find personalized rates:
Rate data provided
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.